GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (NAS:CRVS) » Definitions » Debt-to-Equity

Corvus Pharmaceuticals (Corvus Pharmaceuticals) Debt-to-Equity : 0.04 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Corvus Pharmaceuticals Debt-to-Equity?

Corvus Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.37 Mil. Corvus Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Corvus Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $38.68 Mil. Corvus Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Corvus Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

CRVS' s Debt-to-Equity Range Over the Past 10 Years
Min: -16.35   Med: 0.04   Max: 0.05
Current: 0.04

During the past 10 years, the highest Debt-to-Equity Ratio of Corvus Pharmaceuticals was 0.05. The lowest was -16.35. And the median was 0.04.

CRVS's Debt-to-Equity is ranked better than
76.38% of 1071 companies
in the Biotechnology industry
Industry Median: 0.15 vs CRVS: 0.04

Corvus Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Corvus Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corvus Pharmaceuticals Debt-to-Equity Chart

Corvus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.03 0.04 0.05 0.04

Corvus Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.04 0.04 0.04

Competitive Comparison of Corvus Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Corvus Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corvus Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Corvus Pharmaceuticals's Debt-to-Equity falls into.



Corvus Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Corvus Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Corvus Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corvus Pharmaceuticals  (NAS:CRVS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Corvus Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Corvus Pharmaceuticals (Corvus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
863 Mitten Road, Suite 102, Burlingame, CA, USA, 94010
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.
Executives
Linda S Grais director 86 ALEJANDRA AVE, ATHERTON CA 94027
William Benton Jones officer: See Remarks 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Leiv Lea officer: Chief Financial Officer PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Miller Richard A Md director, officer: President and CEO PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Peter A. Thompson director, 10 percent owner C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Edith P. Mitchell director 1640 MARENGO ST., LOS ANGELES CA 90033
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Mehrdad Mobasher officer: Chief Medical Officer 863 MITTEN ROAD, BURLINGAME CA 94010
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Terry P Gould director, 10 percent owner C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Joseph J Buggy officer: EVP Discovery Research CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Daniel W. Hunt officer: SVP, Chief Business Officer 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Erik J. Verner officer: V.P., Chemistry Research 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010